Package Leaflet: Information for the User
Coaguban 15 mg film-coated tablets EFG
Coaguban 20 mg film-coated tablets EFG
Rivaroxaban
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you
Contents of the package leaflet:
Coaguban contains the active substance rivaroxaban and is used in adults to:
Rivaroxaban belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Coaguban
Do not take Coaguban and inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take rivaroxaban.
Be careful with Coaguban
Inform your doctor if you have any of these situationsbefore taking rivaroxaban. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery:
Children and adolescents
Rivaroxaban is not recommended for children and adolescents under 18 years of age.There is not enough information about its use in children and adolescents.
Other medications and Coaguban
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
If any of the above circumstances apply to you, inform your doctorbefore taking rivaroxaban, as the effect of this medication may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation. If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you also use a preventive treatment.
If any of the above circumstances apply to you, inform your doctorbefore taking rivaroxaban, as the effect of this medication may be reduced. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking this medication. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4 "Possible side effects"). You should not drive or use machines if you are affected by these symptoms.
Coaguban contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Coaguban contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially "sodium-free"
Follow the instructions for administration of this medication indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
What dose to take
The recommended dose is one 20 mg tablet once a day.
If you have kidney problems, the dose may be reduced to one 15 mg tablet once a day.
If you need to undergo a procedure to treat blocked blood vessels in your heart (called percutaneous coronary intervention - PCI with stent placement), there is limited evidence to reduce the dose to one 15 mg rivaroxaban tablet once a day (or to one 10 mg rivaroxaban tablet once a day if your kidneys do not function properly) in addition to an antiplatelet medication such as clopidogrel.
The recommended dose is one 15 mg tablet twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one 20 mg tablet once a day.
After at least 6 months of treatment for blood clots, your doctor may decide to continue treatment with one 10 mg tablet once a day or one 20 mg tablet once a day.
If you have kidney problems and are taking one 20 mg rivaroxaban tablet once a day, your doctor may decide to reduce the dose of the treatment to one 15 mg tablet once a day after 3 weeks if the risk of bleeding is higher than the risk of having another blood clot.
Swallow the tablets, preferably with water. Take Coaguban with food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it.
If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
When to take Coaguban
Take the tablets every day, until your doctor tells you to stop.
Try to take the tablets at the same time every day to remember when to take them. The doctor will decide how long you should continue taking the treatment.
To prevent the formation of blood clots in the brain (stroke) or in other blood vessels: If you need to undergo a procedure to normalize your heartbeat, called cardioversion, take rivaroxaban at the times indicated by your doctor.
If you take more Coaguban than you should
Call your doctor immediately if you have taken too many rivaroxaban tablets. Taking too much medication increases the risk of bleeding. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Coaguban
If you stop taking Coaguban
Do not stop taking rivaroxaban without consulting your doctor first, as this medication treats and prevents serious conditions.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Coaguban can cause adverse effects, although not all people suffer from them.
Like other similar medicines (antithrombotics), rivaroxaban can cause bleeding that can endanger the patient's life. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Possible Adverse Effects that May be Signs of Bleeding:
Inform your doctor immediatelyif you experience any of the following symptoms:
Your doctor may decide to keep you under closer observation or change your treatment.
Possible Adverse Effects that May be Signs of Severe Skin Reaction
Inform your doctor immediatelyif you experience skin reactions such as:
Possible Adverse Effects that May be Signs of Severe Allergic Reaction
Inform your doctor immediatelyif you experience any of the following adverse effects:
General List of Possible Adverse Effects
Common Adverse Effects(may affect up to 1 in 10 patients)
Uncommon Adverse Effects(may affect up to 1 in 100 patients)
Rare Adverse Effects(may affect up to 1 in 1,000 patients)
Frequency Not Known(frequency cannot be estimated from available data)
Reporting of Adverse Effects
If you experience adverse effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es.
By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date shown on the packaging and on each blister after "CAD" or "EXP".
The expiration date is the last day of the month indicated. It does not require special storage conditions.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Coaguban
Tablet core: microcrystalline cellulose, sodium croscarmellose, lactose monohydrate, sodium lauryl sulfate, magnesium stearate, and hypromellose.
Coating of the 15 mg tablet: macrogol 3350, hypromellose, titanium dioxide (E-171), red iron oxide (E-172).
Coating of the 20 mg tablet: macrogol 3350, partially hydrolyzed polyvinyl alcohol, titanium dioxide (E-171), red iron oxide (E-172), and talc.
Appearance of the Product and Package Contents
The film-coated tablets of Coaguban 15 mg are round, biconvex, brown-red in color, engraved with "E3" on one side, and smooth on the other side.
The film-coated tablets of Coaguban 20 mg are round, biconvex, dark red in color, engraved with "E4" on one side, and smooth on the other side.
Coaguban 15 mg
They are packaged in PVC-PVdC/Aluminum blisters, in boxes of 28 or 42 film-coated tablets or in unit-dose blisters, in packages of 100 x 1.
Coaguban 20 mg
They are packaged in PVC-PVdC/Aluminum blisters, in boxes of 28 film-coated tablets or in unit-dose blisters, in packages of 100 x 1.
Marketing Authorization Holder
Towa Pharmaceutical Europe, S.L.
C/ de Sant Martí, 75-97
08107 Martorelles, Barcelona, Spain
Manufacturer
Towa Pharmaceutical Europe, S.L.
C/de Sant Martí, 75-97, 08107, Martorelles, Barcelona, Spain.
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park, PLA3000, Paola, Malta
Date of Last Revision of this Leaflet:October 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://aemps.gob.es/